This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmidt, C. RNAi momentum fizzles as pharma shifts priorities. Nat Biotechnol 29, 93–94 (2011). https://doi.org/10.1038/nbt0211-93
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0211-93
This article is cited by
-
Markets, venture investors and big pharma interest in RNAi soars
Nature Biotechnology (2014)
-
Hepatic RNA interference: delivery by synthetic vectors
Drug Delivery and Translational Research (2014)
-
Targeting cell migration and the endoplasmic reticulum stress response with calmodulin antagonists: a clinically tested small molecule phenocopy of SEC62 gene silencing in human tumor cells
BMC Cancer (2013)
-
UCSD researcher shot by cofounder
Nature Biotechnology (2013)
-
Companies in footrace to deliver RNAi
Nature Biotechnology (2012)